CVS Health reportedly plans to split off its drugstore business
Published November 4, 2026 · Updated November 4, 2026 · 4 sources
Headlines say CVS plans to break off its namesake pharmacies ahead of Q3 earnings. Here is how CVS and three related companies stood at the November 4 close.
The exposed companies and what ATLAS says about each
Price change between the last close before the event and the latest available close. It is a coincidence in time, not a cause-and-effect relationship.
Named in the story as the company planning to split off its drugstore business ahead of Q3 earnings. · Healthcare
CVS is the company named in the story as planning to split off its drugstore business ahead of its third-quarter earnings. Its close was $91.41 on November 3 and $91.41 on November 4, a change of down 0.00%. The sheet lists earnings on November 4 before the open with estimated EPS of 1.65, and a dividend yield of 2.91%.
Price between closes
$91.41 → $91.41Close of November 3 and November 4
Fair value (ATLAS)
$87.64Fair range: $78.88 to $96.41The price ($91.41) is 4.3% above that figure: close to its fair value.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $87.41 and $96.11; 9 in 10, between $80.35 and $104.55.
Cigna's Express Scripts is a pharmacy benefit manager competing with CVS Caremark. · Healthcare
Cigna's Express Scripts is a pharmacy benefit manager competing with CVS Caremark; it is included for its activity in the sector, not because the event affects it. Its close was $295.44 on November 3 and $301.58 on November 4, up 2.08%, a coincidence in time only. Earnings are listed for November 5 before the open, with estimated EPS of 7.51.
Price between closes
$295.44 → $301.58Close of November 3 and November 4
Fair value (ATLAS)
$572.18Fair range: $514.97 to $629.40The price ($301.58) is 47.3% below that figure.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $288.82 and $316.70; 9 in 10, between $266.16 and $343.66.
UnitedHealth's managed care and PBM operations compete with CVS's Aetna and Caremark businesses. · Healthcare
UnitedHealth's managed care and PBM operations compete with CVS's Aetna and Caremark businesses; it is included for its activity in the sector, not because the event affects it. Its close was $404.44 on November 3 and $395.88 on November 4, down 2.12%, a coincidence in time only.
Price between closes
$404.44 → $395.88Close of November 3 and November 4
Fair value (ATLAS)
$414.58Fair range: $373.13 to $456.04The price ($395.88) is 4.5% below that figure: close to its fair value.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $379.36 and $415.54; 9 in 10, between $349.92 and $450.50.
Major pharmaceutical distributor supplying retail pharmacy chains, so a retail restructuring touches its customer base. · Healthcare
McKesson is a major pharmaceutical distributor supplying retail pharmacy chains, so a retail restructuring touches its customer base; it is included for its usual business, with the event as context only. Its close was $999.62 on November 3 and $999.62 on November 4, down 0.00%. Earnings are listed for November 4 after the close, with estimated EPS of 10.75.
Price between closes
$999.62 → $999.62Close of November 3 and November 4
Fair value (ATLAS)
$1,292.34Fair range: $931.46 to $1,824.03The price ($999.62) is 22.7% below that figure.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $961.84 and $1,045.90; 9 in 10, between $893.00 and $1,126.54.
S&P 500 between the same closes (November 3 and November 4): 7,568.92 → 7,689.82 points, +1.60%.
What happened
Headlines from CNBC, The Wall Street Journal and Bloomberg say CVS plans to split off its drugstore business, with Bloomberg describing a break-up of a $117 billion healthcare conglomerate [1][2][3]. TradingView reported that CVS stock rose after hours on the alleged spin-off ahead of its third-quarter earnings report [4].
CNBC's headline says CVS will split off its drugstore business in a major breakup of the healthcare giant [1]. The Wall Street Journal's headline says CVS will break off its namesake pharmacies [2].
Bloomberg's headline says CVS plans to break up a $117 billion healthcare conglomerate [3]. These three sources were available as headlines only, so nothing further is attributed to them.
TradingView's headline says CVS stock rises after hours on an alleged pharmacy spin-off ahead of the Q3 earnings report [4].
What ATLAS data show
ATLAS model estimates put CVS fair value at $87.64, within a range of $78.88 to $96.41, with the November 4 close 4.30% above that value. UnitedHealth's estimate is $414.58 (range $373.13 to $456.04), with its price 4.51% below it. Cigna's estimate is $572.18, with its price 47.29% below, and McKesson's is $1,292.34, with its price 22.65% below. These are model estimates, not promises, and they carry wide ranges.
Price moves and news arriving on the same day are a coincidence in time, not proof that one caused the other. The figures come from closing prices and may change. The S&P 500 rose 1.60% between the November 3 and November 4 closes, so broad market movement also matters.
What you get with ATLAS
Fair value of each company, with its range, against today's price.
Chance of a rise in 1 month and the normal price range, from a calibrated model.
Earnings: next date, estimated EPS and surprise history.
Dividends and alerts by email when a company reports.
Headlines from CNBC, the WSJ and Bloomberg say CVS plans to split off or break off its namesake drugstore business [1][2][3].
Did CVS shares change between the November 3 and November 4 closes?
No. The close was $91.41 on both dates, a change of down 0.00%. TradingView's headline refers to a rise after hours [4].
Why are Cigna, UnitedHealth and McKesson mentioned?
Cigna and UnitedHealth have PBM and managed care businesses that compete with CVS, and McKesson supplies retail pharmacies. They are included for their sector activity, not because the event affects them.
Closing prices, fair value, probabilities, earnings and dividends: ATLAS own data as of November 4, 2026. How we calculate fair value.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy
ATLAS